Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Ho-Young Yhim, MD, Cheolwon Suh, Seok Jin Kim, MD PhD, Deok-Hwan Yang, MD PhD, Hyeon-Seok Eom, MD, Kyoung Ha Kim, MD PhD, Yong Park, Jin Seok Kim, MD PhD, Hyo Jung Kim, MD PhD, Dok Hyun Yoon, MD PhD, Won Seog Kim, MD PhD, Jae-Yong Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 4076.

https://doi.org/10.1182/blood-2019-122631

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Pigment Epithelium-Derived Factor Promotes the Angiogenic Activity of VEGF

Jeong-A Kim, MD PhD, Misuk Yang, Young Hoon Park, MD, Youngrok Park, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 3687.

https://doi.org/10.1182/blood-2018-99-117420

Published: 2018

Journal Articles

Prognostic Significance of FDG-PET/CT on Determining Upfront Autologous Stem Cell Transplantation for the Treatment of Peripheral T Cell Lymphomas

Seo-Yeon Ahn, MD, Seung-Yeon Jung, Sung-Hoon Jung, MD, Jae-Sook Ahn, MD PhD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Sae-Ryung Kang, MD, Yeon-Hee Han, MD, Jae-Yong Kwak, MD PhD, Ho-Young Yhim, MD PhD, Deok-Hwan Yang, MD PhD

Blood (2018) 132 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2018-99-118168

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Risk Stratification Integrating Deauville Score on Interim PET-CT Scan and Baseline International Prognostic Index in Diffuse Large B-Cell Lymphoma Patients

Ho-Young Yhim, MD PhD, Sung Kyun Yim, So Yeon Jeon, MD, Yeon-Hee Han, MD, Myung-Hee Sohn, Na-Ri Lee, Eun-Kee Song, MD, Chang-Yeol Yim, Hee Sun Kim, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2018-99-114365

Published: 2018

Journal Articles

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Ho-Young Yhim, MD PhD, Yong Park, MD, Joon Ho Moon, MD, Ho-Jin Shin, MD PhD, Yoon Seok Choi, MD, Min Kyoung Kim, MD PhD, Dae Sik Kim, MD PhD, Ji Hyun Lee, MD PhD, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Jun Soo Ham, MD, Seok Jin Kim, MD PhD, Won Seog Kim, MD PhD, Deok-Hwan Yang, MD, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2018-99-115620

Published: 2018

Journal Articles

Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia

Hayeon Noh, Su Young Jung, Jae-Yong Kwak, MD PhD, Sung-Hyun Kim, Suk Joong Oh, Dae Young Zang, Hye Lin Park, Dae Jin Jo, Jae Soo Shin, Young Rok Do, Dong-Wook Kim, MD PhD, Jangik I Lee

Blood (2016) 128 (22): 3086.

https://doi.org/10.1182/blood.V128.22.3086.3086

Published: 2016

Journal Articles

Fractalkine/CX3CR1 Signaling Promotes Angiogenic Potentials in CX3CR1 Expressing Monocytes

Jeong A Kim, MD PhD, Jae-Yong Kwak, MD PhD, Yhim Eunjung, MD, Joon Lee, Youngrok Park, Hal E. Broxmeyer, PhD

Blood (2016) 128 (22): 2507.

https://doi.org/10.1182/blood.V128.22.2507.2507

Published: 2016

Journal Articles

Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Dok Hyun Yoon, MD PhD, Seok Jin Kim, MD PhD, Seong Hyun Jeong, MD, Dong-Yeop Shin, MD, Sung Hwa Bae, MD, Junshik Hong, MD, Seong Kyu Park, MD, Ho-Young Yhim, MD, Deok-Hwan Yang, MD, Hye Won Lee, MD, Mark Lee, MD PhD, Hyeonseok Eom, MD, PhD, Jae-Yong Kwak, MD PhD, Jae Hoon Lee, Cheolwon Suh, Won Seog Kim, MD PhD

Blood (2015) 126 (23): 3942.

https://doi.org/10.1182/blood.V126.23.3942.3942

Published: 2015

Journal Articles

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Blood (2014) 124 (21): 3155.

https://doi.org/10.1182/blood.V124.21.3155.3155

Published: 2014

Journal Articles

The Role of CD11b+CX3CR1+ Cells in Neovascularization

Jeong-A Kim, MD PhD, Jae-Yong Kwak, MD PhD, Kyoungmi Noh, Joon Lee, Youngrok Park, Hal E. Broxmeyer, PhD

Blood (2014) 124 (21): 4180.

https://doi.org/10.1182/blood.V124.21.4180.4180

Published: 2014

Journal Articles

Long-Term Follow-up Results after Imatinib Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

Ho-Young Yhim, MD PhD, Na Ri Lee, MD PhD, Eun-Kee Song, MD PhD, Chang-Yeol Yim, MD PhD, So Yeon Jeon, MD, Bohee Lee, MD, Jeong-A Kim, MD PhD, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak, MD PhD

Blood (2014) 124 (21): 4553.

https://doi.org/10.1182/blood.V124.21.4553.4553

Published: 2014

Journal Articles

Clinical Outcomes and Prognostic Factors of Front-Line Autologous Stem Cell Transplantation in Patients with Extranodal NK/T-Cell Lymphoma

Ho-Young Yhim, MD PhD, Jin Seok Kim, Yeung-Chul Mun, Chu-Myong Seong, Joon Ho Moon, Yong Park, MD PhD, Jae-Cheol Jo, MD, Seok Jin Kim, MD PhD, Jae-Yong Kwak, MD PhD, Je-Jung Lee, MD PhD, Deok-Hwan Yang, MD PhD

Blood (2014) 124 (21): 2523.

https://doi.org/10.1182/blood.V124.21.2523.2523

Published: 2014

Journal Articles

Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib

Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, Yun Jeong Oh, Hae Lyun Yoo, Eun-Jung Jang, Mi-yeon Choi, Moon-mi Jang, Hyeoung Joon Kim, MD, Jae-Yong Kwak, MD PhD, Hawk Kim, MD, PhD., Young-Rok Do, PhD, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 5511.

https://doi.org/10.1182/blood.V124.21.5511.5511

Published: 2014

Journal Articles

Phase II Trial Of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (methotrexate, ifosfamide, etoposide, dexamethasone, and L-asparaginase) Chemotherapy For Patients With Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Seok Jin Kim, MD, PhD, Dok Hyun Yoon, MD, Seong Hyun Jeong, Dong-Yeop Shin, MD, Sung Hwa Bae, Junshik Hong, MD, Eun Kyung Park, Se Hyung Kim, Ho-Young Yhim, MD, Deok-Hwan Yang, MD, Hye Won Lee, Je-Jung Lee, MD, PhD, Mark Lee, MD, PhD, Hyeon Seok Eom, MD, PhD, Jae-Yong Kwak, MD, PhD, Jae Hoon Lee, Dae Sik Hong, Cheolwon Suh, Won Seog Kim

Blood (2013) 122 (21): 3037.

https://doi.org/10.1182/blood.V122.21.3037.3037

Published: 2013

Journal Articles

The Role Of CD11b+CX3CR1+ Cells In Neovascularization

Jeong-A Kim, MD, PhD, Jae-Yong Kwak, MD, PhD, Kyoungmi Noh, Hyun-Kyung Kim, PhD, Bohee Lee, MD, Youngrok Park, Young June Kim, PhD, Hal E. Broxmeyer, PhD

Blood (2013) 122 (21): 2301.

https://doi.org/10.1182/blood.V122.21.2301.2301

Published: 2013

Journal Articles

Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation

Blood (2013) 122 (21): 5379.

https://doi.org/10.1182/blood.V122.21.5379.5379

Published: 2013

Journal Articles

Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration

Rachid Baz, MD, Hui-Yi Lin, PhD, Sung-Soo Yoon, MD, Kihyun Kim, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Dan Sullivan, MD, Hye Jin Kang, Jin Seok Kim, MD, Cheolwon Suh, Je-Jung Lee, MD, PhD, Jeong-A Kim, MD, PhD, Yang Soo Kim, MD, Chang-Ki Min, MD, Jae-Yong Kwak, MD, PhD, Sung-Hyun Kim, MD, PhD, Won Sik Lee, MD, Junshik Hong, MD, Jae Hoon Lee, MD

Blood (2013) 122 (21): 3201.

https://doi.org/10.1182/blood.V122.21.3201.3201

Published: 2013

NARROW

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Pigment Epithelium-Derived Factor Promotes the Angiogenic Activity of VEGF

Prognostic Significance of FDG-PET/CT on Determining Upfront Autologous Stem Cell Transplantation for the Treatment of Peripheral T Cell Lymphomas

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Risk Stratification Integrating Deauville Score on Interim PET-CT Scan and Baseline International Prognostic Index in Diffuse Large B-Cell Lymphoma Patients

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia

Fractalkine/CX3CR1 Signaling Promotes Angiogenic Potentials in CX3CR1 Expressing Monocytes

Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

The Role of CD11b+CX3CR1+ Cells in Neovascularization

Long-Term Follow-up Results after Imatinib Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

Clinical Outcomes and Prognostic Factors of Front-Line Autologous Stem Cell Transplantation in Patients with Extranodal NK/T-Cell Lymphoma

Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib

Phase II Trial Of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (methotrexate, ifosfamide, etoposide, dexamethasone, and L-asparaginase) Chemotherapy For Patients With Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

The Role Of CD11b+CX3CR1+ Cells In Neovascularization

Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation

Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only